You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.
The company hopes the data will help convince clinicians to adopt the algorithm in CRC as it pushes forward validations for other areas like pancreatic and ovarian tumors.
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
The drugmaker will work with McKesson's Ontada to gather real-world data insights on molecular testing and cancer treatment patterns and identify access gaps.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
The test uses a targeted methylation sequencing panel to detect more than 50 cancer types across all stages and pinpoint a cancer's tissue of origin.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.
As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Through Wamberg Genomic Advisors, SCOR life insurance policyholders can access genetic testing to better understand their own cancer risk and therapy options.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.